Henan Newland Pharmaceutical Co. Ltd. A (301277) — Cash Flow-to-Debt Ratio
Henan Newland Pharmaceutical Co. Ltd. A (301277) has a Cash Flow-to-Debt Ratio of 0.51x as of December 2025, meaning its operating cash flow of CN¥116.94 Million could theoretically repay 1% of its total liabilities (CN¥228.49 Million) in one year. See cash generation quality of Henan Newland Pharmaceutical Co. Ltd. A to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Henan Newland Pharmaceutical Co. Ltd. A Cash Flow-to-Debt Ratio (2020–2025)
Historical debt coverage capacity for Henan Newland Pharmaceutical Co. Ltd. A across 6 annual periods. Also explore Henan Newland Pharmaceutical Co. Ltd. A (301277) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
Year-by-year debt coverage analysis for Henan Newland Pharmaceutical Co. Ltd. A. For market capitalisation and broader financial context, see 301277 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.51x | CN¥116.94 Million | CN¥228.49 Million | ▲ +9.3% |
| 2024 | 0.47x | CN¥126.76 Million | CN¥270.69 Million | ▼ -71.1% |
| 2023 | 1.62x | CN¥259.46 Million | CN¥160.02 Million | ▲ +241.7% |
| 2022 | 0.47x | CN¥82.85 Million | CN¥174.58 Million | ▲ +152.9% |
| 2021 | 0.19x | CN¥49.08 Million | CN¥261.53 Million | ▼ -18.2% |
| 2020 | 0.23x | CN¥47.86 Million | CN¥208.57 Million | — |